Table 3.

Rate Ratios (95% CI) of Thromboembolism and Major Bleeding Associated With Long‐Term Adherence Trajectories

	Adjusted RR (95% CI) (early discontinuation vs consistent adherence)			Adjusted RR (95% CI) (gradual decline vs consistent adherence)
	Total	First 12 mo	After 12 mo	Total	First 12 mo	After 12 mo
Total patients
Thromboembolism (N=18 920)	1.40† (1.05–1.86)	0.86 (0.52–1.42)	2.22† (1.41–3.50)	0.74 (0.46–1.19)	…	1.51 (0.84–2.73)
Major bleed (N=18 940)	0.48† (0.30–0.75)	0.36† (0.17–0.77)	0.82 (0.41–1.64)	0.40† (0.20–0.73)	0.11† (0.02–0.82)	0.78 (0.36–1.70)
For patients with CHA2D2‐VASc ≥2 and no previous warfarin use
Thromboembolism (N=10 677)	1.29 (0.89–1.86)	0.78 (0.42–1.45)	2.21† (1.20–4.07)	0.83 (0.45–1.53)	…	1.89 (0.89–4.06)
Major bleed (N=10 689)	0.42† (0.23–0.77)	0.22† (0.07–0.70)	0.85 (0.36–2.00)	0.46 (0.20–1.04)	…	1.26 (0.53–3.00)

… no observation. For thromboembolism, age, sex, race and ethnicity, CHA₂D₂‐VASc, prior warfarin use, and creatinine clearance were adjusted in the model. For major bleed, age, sex, race and ethnicity, CHA₂D₂‐VASc, HAS‐BLED, prior warfarin use, creatinine clearance, dementia, and injurious falls were adjusted. RR indicates rate ratio.

^* P<0.05.